| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT05316701) | Orca Biosystems, Inc. | 2022-06-21 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients (NCT05433532) | The First Affiliated Hospital of Soochow University | 2022-05-01 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (NCT04726241) | PedAL BCU, LLC | 2022-04-18 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516) | Syndax Pharmaceuticals | 2022-03-09 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767) | University of Washington | 2022-02-04 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588) | Center for International Blood and Marrow Transplant Research | 2021-09-30 |
| Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia (NCT04762485) | The First Affiliated Hospital of Soochow University | 2021-06-01 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (NCT03957915) | Institut Paoli-Calmettes | 2020-05-29 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting (NCT04128501) | M.D. Anderson Cancer Center | 2020-05-05 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (NCT04065399) | Syndax Pharmaceuticals | 2019-11-05 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (NCT03959085) | Children's Oncology Group | 2019-10-31 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (NCT04067336) | Kura Oncology, Inc. | 2019-09-12 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (NCT03779854) | Fred Hutchinson Cancer Center | 2019-08-29 |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation (NCT03843528) | Johns Hopkins All Children's Hospital | 2019-05-01 |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT03802695) | Orca Biosystems, Inc. | 2019-04-08 |
| Management of Mixed-Phenotype Acute Leukemia in the East of France (NCT03599869) | Central Hospital, Nancy, France | 2018-09-01 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders (NCT03198234) | Roncarolo, Maria Grazia, MD | 2017-08-30 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT03007147) | Children's Oncology Group | 2017-08-08 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (NCT02828358) | National Cancer Institute (NCI) | 2017-04-01 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS (NCT02921061) | Fred Hutchinson Cancer Center | 2016-11-17 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (NCT02135874) | M.D. Anderson Cancer Center | 2014-10-27 |
| Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia (NCT01887587) | Ehab L Atallah | 2013-06-01 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |